170033-64-4

Usage

Uses

Used in Pharmaceutical Applications:
(S)-2-amino-N-benzyl-N-((R)-2-hydroxypropyl)propanamide is used as a potential pharmaceutical compound for its structural similarity to amino acids, which are crucial for protein synthesis in the body. Its potential applications may include the development of new drugs targeting various diseases and conditions.
Used in Drug Design and Development:
In the field of drug design and development, (S)-2-amino-N-benzyl-N-((R)-2-hydroxypropyl)propanamide can be used as a starting point for creating new molecules with specific biological activities. Its unique structure may allow for the development of targeted therapies for various medical conditions.
Used in Research and Development:
(S)-2-amino-N-benzyl-N-((R)-2-hydroxypropyl)propanamide is used as a research compound to study its interactions with biological systems and to explore its potential as a therapeutic agent. This may involve testing its effects on cellular processes, enzyme activity, and other biological targets.
Used in Chemical Synthesis:
(S)-2-amino-N-benzyl-N-((R)-2-hydroxypropyl)propanamide can be used as a building block or intermediate in the synthesis of more complex organic compounds, potentially leading to the development of novel pharmaceuticals or other useful materials.

Upstream product

• 100-52-7 benzaldehyde 
• 162240-94-0 (R)-1-<(Phenylmethyl)amino>-2-propanol 
• 162150-53-0 (S)-<2-<(2(R)-Hydroxypropyl)(phenylmethyl)amino>-1-methyl-2-oxoethyl>carbamic acid 1,1-dimethylethyl ester 

Downstream Products

• 162240-96-2 (2S,6S)-2,6-dimethylpiperazine dihydrochloride 
• 162240-95-1 (3S,5S)-3,5-Dimethyl-1-(phenylmethyl)piperazine 
• 162150-54-1 (R)-1-<(2(S)-Aminopropane)(phenylmethyl)amino>-2-propanol 

Relevant academic research and scientific papers

TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

Asymmetric Synthesis of 2,6-Methylated Piperazines

The complete series of enantiopure 2,6-methylated piperazines was synthesized utilizing two alternative reactions in the key bond-forming step.The dimethyl enantiomers, (2R,6R)- and (2S,6S)-2,6-dimethylpiperazine (1, 2), were prepared using either a diastereoselective triflate alkylation or a novel intermolecular Mitsunobu reaction to set the required stereochemistry.The monomethyl derivatives, (R)- and (S)-tert-butyl 2-methyl-1-piperazinecarboxylate (3, 4) were also synthesized employing the Mitsunobu cyclization strategy while the trimethyl compounds, (R)- and (S)-2,2,6- trimethylpiperazine (5, 6) were prepared using an enantiospecific triflate alkylation as the principal reaction.These methods represent efficient, general strategies for preparing a variety of 2,6-methylated piperazines for which the absolute stereochemistry can be readily controlled.

Asymmetric Synthesis of (2R,6R) and (2S,6S)-2,6-Dimethylpiperazine

The title compounds were prepared via two efficient routes.The first sequence utilized a diastereospecific triflate alkylation in the key bond forming step while the second method relied on a novel intramolecular Mitsunobu reaction to set the required stereochemistry.